News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article first appeared on GuruFocus. Evaluating the Upcoming Payout and Long-Term Sustainability Banco BBVA Argentina SA (NYSE:BBAR) recently announced a total dividend of $0.08 per share, with the ex-dividend date set for 2026-08-03. This upcoming payment includes a cash dividend of $0.08 per …
Sharemaestro market context Trend signal active 52 weeks +34.3% · Next-week setup positive 57.2%This article provides financial information for Banco BBVA Argentina SA, specifically focusing on its invested assets to total deposits. It lists the stock symbol BCBA:BBAR.CI on the Buenos Aires Stock Exchange and highlights the company's financials, documents, news, and technical analysis. The content is …
AbbVie (ABBV) has successfully diversified its business beyond its previous dependence on Humira, with strong Q2 revenue and earnings growth driven by its Immunology and Neurosciences segments. Analysts maintain a "Moderate Buy" rating, anticipating the stock could reach $300 within 12 months, despite a …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%Dimensional Fund Advisors LP increased its stake in BrightView Holdings, Inc. by 3.8% in the first quarter, acquiring an additional 192,376 shares, bringing its total holdings to 5.27 million shares. This represents about 5.59% of the company, which is 92.41% institutionally owned. BrightView recently …
This article lists various ETFs that include Pharvaris N.V. (A2QNWS) stocks in their holdings. It provides detailed information for each ETF, such as market value, weight of Pharvaris N.V. stock, issuer, management style, expense ratio, AUM, price, and performance metrics like 3-year NAV total …
As of March 2026, AbbVie (ABBV) has approximately 57,960 total employees worldwide, a growth of 11.0% since 2023. The company is actively hiring, with 2,862 job postings in 2026, and its workforce is concentrated in the United States, followed by India and Ireland. The …
Pharvaris N.v. (NASDAQ: PHVS) is showing weak near and mid-term sentiment, despite a positive long-term outlook, with resistance currently being tested. An exceptional 30.0:1 risk-reward short setup is identified, targeting 8.2% downside against 0.3% risk. The article outlines institutional trading strategies including position trading, …
Banco BBVA Argentina (BFP) announced its Q4 2025 earnings, reporting actual EPS of €0.16 against a consensus of €0.38, missing by -€0.21. However, the company's revenue of €1.11B significantly beat the expected €553.61M. Despite a YoY revenue decline of 10.47%, the company showed strong …
This article provides the "Price to sales forward" metric for BV Financial, Inc. (NASDAQ: BVFL) on TradingView. It appears to be a stub or a data point within a larger financial analysis platform, showing basic company and market information. The content primarily consists of …
AbbVie has revised its full-year profit forecast downwards as a direct consequence of its recent acquisition of Apogee Therapeutics. This adjustment reflects the financial impact and integration costs associated with the acquisition, signaling a change in the company's expected earnings for the fiscal year.
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%ProQR Therapeutics N.V. (NASDAQ: PRQR) generated $19.14 million in revenue last year, with its RNA Based Therapeutics segment being the top performer, contributing $17.95 million. The United States was the primary geographic contributor, also accounting for $17.95 million. This represents a slight decrease from …
BV Financial Inc (BVFL) currently holds a stable financial score of 6.38, ranking 278 out of 394 in the Banking Services industry, despite having low operating efficiency. The company reported a quarterly revenue of $9.63 million, marking a 3.39% year-over-year increase, and a net …
This article focuses on the enterprise value to revenue forward metric for BV Financial, Inc. (NASDAQ: BVFL). It appears to be a stub or an incomplete financial data point from a larger platform. The content primarily lists market data providers and copyright information, without …
AbbVie's stock fell by nearly 3% after its second-quarter earnings report, despite strong revenue growth, because its adjusted profitability of $3.65 per share missed analyst estimates of $3.71. Additionally, the company slightly cut its 2026 profitability outlook due to its acquisition of Apogee Therapeutics, …
AbbVie's key drugs Skyrizi and Rinvoq are providing strong support for the company's lengthy patent protection and wide economic moat. Despite biosimilar competition impacting Humira revenue in 2023, AbbVie returned to growth in 2024, demonstrating the resilience of its diversified portfolio. The company maintains …
AbbVie (ABBV) has received European Commission approval for its drug RINVOQ (upadacitinib) for new indications in the EU. RINVOQ is now approved as the first systemic treatment for non-segmental vitiligo and as a systemic option for severe alopecia areata in adults and adolescents. These …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%This article provides a comprehensive stock analysis of Banco Bbva Argentina SA (BBAR) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and fair valuation, ranking 150 out of 394 in the Banking Services industry. The analysis also covers analyst ratings, institutional …
This article first appeared on GuruFocus. Release Date: July 31, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbbVie Inc (NYSE:ABBV) delivered another excellent quarter with total net revenues of nearly $17 billion, …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%DBV Technologies' Chief Medical Officer, Mohideen Pharis, sold 464 ordinary shares at $2.70 per share on July 29, 2026. This transaction was executed to cover withholding tax obligations arising from the vesting of restricted stock units. After the sale, Pharis directly holds 144,531 ordinary …
This article provides a risk assessment for ABVC Biopharma Inc (ABVC), noting its current risk score of 3.01 and ranking within the Biotechnology & Medical Research industry. It details the company's beta value of 0.54, indicating lower volatility compared to the S&P 500, and …
AbbVie slashes its full-year guidance to account for its pending acquisition of Apogee Therapeutics. Continue Reading
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie ABBV reported second-quarter 2026 adjusted EPS of $3.65, which beat the Zacks Consensus Estimate of $3.64. The reported figure also exceeded the company's guidance of $3.57-$3.61 per share, issued earlier in July 2026. Earnings rose 22.9% year over year. ABBV's revenues of $16.99 …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%This article first appeared on GuruFocus. AbbVie (NYSE:ABBV) fell 3.46% premarket after trimming full-year guidance alongside second-quarter results that beat on both lines. Net revenues rose 10.2% to $16.99 billion against the $16.78 billion analysts expected, and adjusted diluted earnings of $3.65 a share …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie (NYSE: ABBV) shares fell after the company trimmed its full-year earnings guidance, despite reporting strong second-quarter earnings and revenue beats. The guidance reduction is primarily attributed to the anticipated acquisition of Apogee Therapeutics, which is expected to negatively impact 2026 earnings, although underlying …
For the quarter ended June 2026, AbbVie (ABBV) reported revenue of $16.99 billion, up 10.2% over the same period last year. EPS came in at $3.65, compared to $2.97 in the year-ago quarter. The reported revenue represents a surprise of +1.07% over the Zacks …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie beat second-quarter profit estimates due to strong immunology sales but announced a cut in its full-year adjusted earnings forecast by 14 cents per share. This reduction is attributed to the planned acquisition of Apogee Therapeutics for approximately $10.9 billion. The stock subsequently dropped …
AbbVie's (NYSE:ABBV) Q2 CY2026: Beats On Revenue Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts' consensus estimates. Is now …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie (ABBV) came out with quarterly earnings of $3.65 per share, beating the Zacks Consensus Estimate of $3.64 per share. This compares to earnings of $2.97 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate. Adjusted earnings per share came in at $3.65, missing analyst estimates of $3.71, while revenue of $16.99 billion exceeded the consensus …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%Search by ticker symbol or company name and select a result to open its chart.